Nitazoxanide and Lansoprazole Based Regimens for H. Pylori Management
NCT ID: NCT05184491
Last Updated: 2022-01-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
500 participants
INTERVENTIONAL
2021-10-15
2022-03-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Nitazoxanide (NTZ) Based New Therapeutic Regimens for Helicobacter Pylori
NCT02422706
Study of Nitazoxanide (NTZ) for Helicobacter Pylori in Children
NCT04415983
Non-invasive Test-guided Tailored Therapy Versus Empiric Treatment for Helicobacter Pylori Infection.
NCT04107194
Vonoprazan-based Therapy Versus Standard Regimen for Helicobacter Pylori Infection Management
NCT05614934
One vs Two Weeks Treatment for H.Pylori Eradication A RANDOMIZED NON-INFERIORITY PLACEBO CONTROLLED TRIAL
NCT05728424
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Naïve patients - ACO therapy
One hundred patients naive to H. Pylori eradication therapy will receive ACO therapy for 14 days (amoxicillin 1 g with breakfast and dinner, clarithromycin 500 mg with breakfast and dinner and lansoprazole 40 mg twice daily before meals).
Naïve patients - ACO therapy
Naïve patients will receive classic triple therapy (amoxicillin, clarithromycin and lansoprazole) for 14 days
Naïve patients - LNDL therapy
One hundred patients naive to H. Pylori eradication therapy will receive LNDL therapy for 14 days (Levofloxacin 750 mg with breakfast, nitazoxanide 500 mg twice daily with meals, doxycycline 100 mg twice daily and Lansoprazole 40 mg twice daily before meals)
Naïve patients - LNDL therapy
Naïve patients will receive Levofloxacin, nitazoxanide, doxycycline and Lansoprazole for 14 days
Naïve patients - MNDL therapy
One hundred patients naive to H. Pylori eradication therapy will receive MNDL therapy for 14 days ( Moxifloxacin 400 mg with breakfast, nitazoxanide 500 mg twice daily with meals, doxycycline 100 mg twice daily and Lansoprazole 40 mg twice daily before meals)
Naïve patients - MNDL therapy
Naïve patients will receive Moxifloxacin, nitazoxanide, doxycycline and Lansoprazole for 14 days
Treatment-experienced patients- LNDL therapy
One hundred patients who were unresponsive to previous eradication therapy will receive LNDL therapy for 14 days (Levofloxacin 750 mg with breakfast, nitazoxanide 500 mg twice daily with meals, doxycycline 100 mg twice daily and Lansoprazole 40 mg twice daily before meals)
Treatment-experienced patients- LNDL therapy
Experienced patients will receive Levofloxacin, nitazoxanide, doxycycline and Lansoprazole for 14 days
Treatment-experienced patients- MNDL therapy
One hundred patients who were unresponsive to previous eradication therapy will receive MNDL therapy for 14 days ( Moxifloxacin 400 mg with breakfast, nitazoxanide 500 mg twice daily with meals, doxycycline 100 mg twice daily and Lansoprazole 40 mg twice daily before meals)
Treatment-experienced patients- MNDL therapy
Experienced patients will receive Moxifloxacin, nitazoxanide, doxycycline and Lansoprazole for 14 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Naïve patients - ACO therapy
Naïve patients will receive classic triple therapy (amoxicillin, clarithromycin and lansoprazole) for 14 days
Naïve patients - LNDL therapy
Naïve patients will receive Levofloxacin, nitazoxanide, doxycycline and Lansoprazole for 14 days
Naïve patients - MNDL therapy
Naïve patients will receive Moxifloxacin, nitazoxanide, doxycycline and Lansoprazole for 14 days
Treatment-experienced patients- LNDL therapy
Experienced patients will receive Levofloxacin, nitazoxanide, doxycycline and Lansoprazole for 14 days
Treatment-experienced patients- MNDL therapy
Experienced patients will receive Moxifloxacin, nitazoxanide, doxycycline and Lansoprazole for 14 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Future pharmaceutical industries
UNKNOWN
National Liver Institute, Egypt
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Gasser Ibrahim El-Azab
Professor of Hepatology and Gastroenterology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gasser El-Azab, M.D.
Role: PRINCIPAL_INVESTIGATOR
National Liver Institute
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Liver institute - Menoufia University
Shibīn al Kawm, Menoufia, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
01013334106
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.